Iovance Biotherapeutics Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript
Hello, it's now my pleasure to introduce Dr. Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics. The format for this session is roughly a 25-minute fireside chat, and if you have any questions in the session, feel free to type them into the question box and we'll try to ask them on your behalf. Igor, Iovance recently completed its BLA submission for the salicylic melanoma, which was an important step for the company.
Maybe to start off, can you give us a brief overview of Iovance' [skilled] programs and the company's strategic approach to manufacturing, and then we'll dive into the details a little bit more. Great to have you.
Happy to. Thank you, Gorilla. Good afternoon, Gorilla. Good afternoon, everyone. Great to be here. Iovance --
Actually, I'll start with forward-looking statements. We're a publicly listed company. I'll be making forward-looking statements as part of this discussion. I refer you to our filings with the SEC for a full
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
